<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        122-124-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PEDEXA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pedexa is used for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.<br />Pedexa belongs to a group of medicinal products called nonsteroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as (COX-2) inhibitors. Your body makes prostaglandins that may cause pain and inflammation. In conditions such as rheumatoid arthritis and osteoarthritis your body makes more of these. Pedexa acts by reducing the production of prostaglandins, thereby reducing the pain and inflammation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You have been prescribed Pedexa by your doctor. The following information will help you get the best results with Pedexa. If you have any further questions please ask your doctor or pharmacist.<br />Do not take Pedexa<br />Tell your doctor if any of the following are true for you as patients with these conditions should not take Pedexa.<br />&bull; if you are allergic to celecoxib or any of the other ingredients of Pedexa<br />&bull; if you have had an allergic reaction to a group of medicines called &ldquo;sulfonamides&rdquo; (e.g. some antibiotics used to treat infections)<br />&bull; if you currently have an ulcer in your stomach or intestines, or bleeding in your stomach or intestines<br />&bull; if as a result of taking acetylsalicylic acid or any other anti-inflammatory and painrelieving medicine (NSAID) you have had asthma, nose polyps, severe nose congestion, or an allergic reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing difficulties or wheezing<br />&bull; if you are pregnant. If you can become pregnant during ongoing treatment you should discuss methods of contraception with your doctor<br />&bull; if you are breast-feeding<br />&bull; if you have severe liver disease<br />&bull; if you have severe kidney disease<br />&bull; if you have an inflammatory disease of the intestines such as ulcerative colitis or Crohn&rsquo;s disease<br />&bull; if you have heart failure, established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina, or blockages of blood vessels to the heart or brain<br />&bull; if you have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs<br />Take special care with Pedexa<br />Talk to your doctor or pharmacist before taking Pedexa&reg;:<br />&bull; if you have previously had an ulcer or bleeding in your stomach or intestines. (Do not take Pedexa if you currently have an ulcer or bleeding in your stomach or intestine)<br />&bull; if you are taking acetylsalicylic acid (even at low dose for heart protective purposes)<br />&bull; if you use medicines to reduce blood clotting (e.g. warfarin/ warfarin like anticoagulants or novel oral anti-clotting medicines, e.g. apixaban)<br />&bull; if you use medicines called corticosteroids (e.g. prednisone).<br />&bull; if you are using Pedexa at the same time as other non-acetylsalicylic NSAIDs such as ibuprofen or diclofenac. The use of these medicines together should be avoided<br />&bull; if you smoke, have diabetes, raised blood pressure or raised cholesterol<br />&bull; if your heart, liver or kidneys are not working well your doctor may want to keep a regular check on you<br />&bull; if you have fluid retention (such as swollen ankles and feet)<br />&bull; if you are dehydrated, for instance due to sickness, diarrhoea or the use of diuretics (used to treat excess fluid in the body)<br />&bull; if you have had a serious allergic reaction or a serious skin reaction to any medicines<br />&bull; if you feel ill due to an infection or think you have an infection, as Pedexa may mask a fever or other signs of infection and inflammation<br />&bull; if you are over 65 years of age your doctor will want to monitor you regularly.<br />&bull; the consumption of alcohol and NSAIDs may increase the risk of gastrointestinal problems<br />As with other NSAIDs (e.g. ibuprofen or diclofenac) this medicine may lead to an increase in blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis.<br />Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib.<br />Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.<br />Pedexa may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant.<br />Taking other medicines, herbal or dietary supplements<br />Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines:<br />&bull; Dextromethorphan (used to treat coughs)<br />&bull; ACE inhibitors or angiotensin II antagonists, beta blockers and diuretics (used for high blood pressure and heart failure)<br />&bull; Fluconazole and rifampicin (used to treat fungal and bacterial infections)<br />&bull; Warfarin or other warfarin like medicines (&ldquo;blood-thinning&rdquo; agents that reduce blood clotting) including newer medicines like apixaban.<br />&bull; Lithium (used to treat some types of depression)<br />&bull; Other medicines to treat depression, sleep disorders, high blood pressure or an irregular heartbeat<br />&bull; Neuroleptics (used to treat some mental disorders)<br />&bull; Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)<br />&bull; Carbamazepine (used to treat epilepsy/seizures and some forms of pain or depression)<br />&bull; Barbiturates (used to treat epilepsy/seizures and some sleep disorders)<br />&bull; Ciclosporin and tacrolimus (used for immune system suppression e.g. after transplants)<br />Pedexa can be taken with low dose acetylsalicylic acid (75mg or less daily). Ask your doctor for advice before taking both medicines together.<br />Pregnancy and breastfeeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Pregnancy<br />Pedexa must not be used by women who are pregnant or can become pregnant (i.e. women of child bearing potential who are not using adequate contraception) during<br />ongoing treatment. If you become pregnant during treatment with Pedexa you should discontinue the treatment and contact your doctor for alternative treatment.<br />Breast-feeding<br />Pedexa must not be used during breast-feeding.<br />Fertility<br />NSAIDs, including Pedexa&reg;, may make it more difficult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.<br />Driving and using machines<br />You should be aware of how you react to Pedexa before you drive or operate machinery. If you feel dizzy or drowsy after taking Pedexa, do not drive or operate machinery until these effects wear off.<br />Important information about some of the ingredients of Pedexa<br />Pedexa capsules contain lactose, if you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Pedexa exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure. If you think or feel that the effect of Pedexa is too strong or too weak, talk to your doctor or pharmacist.<br />Your doctor will tell you what dose you should take. As the risk of side effects associated with heart problems may increase with dose and duration of use, it is important that you use the lowest dose that controls your pain and you should not take Pedexa for longer than necessary to control symptoms.<br />Method of administration:<br />Pedexa is for oral use. The capsules can be taken at any time of the day, with or without food. However, try to take each dose of Pedexa at the same time each day.<br />If you have difficulty swallowing capsules: The entire capsule contents can be sprinkled onto a level teaspoon of semi-solid food (such as cool or room temperature applesauce, rice gruel, yogurt or mashed banana) and swallowed immediately with a drink approximately 240 ml of water.<br />To open the capsule, hold upright to contain the granules at the bottom then gently squeeze the top and twist to remove, taking care not to spill the contents. Do not chew or crush the granules.<br />Contact your doctor within two weeks of starting treatment if you do not experience any benefit.<br />The recommended dose is:<br />For osteoarthritis the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.<br />The dose is usually:<br />&bull; one 200 mg capsule once a day; or<br />&bull; one 100 mg capsule twice a day.<br />For rheumatoid arthritis the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.<br />The dose is usually:<br />&bull; one 100 mg capsule twice a day.<br />For ankylosing spondylitis, the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400mg, if needed.<br />The dose is usually:<br />&bull; one 200 mg capsule once a day; or<br />&bull; one 100 mg capsule twice a day.<br />Kidney or liver problems: make sure your doctor knows if you have liver or kidney problems as you may need a lower dose.<br />The elderly, especially those with a weight less than 50 kg: if you are over 65 years of age and especially if you weigh less than 50 kg, your doctor may want to monitor you more closely.<br />You should not take more than 400 mg per day.<br />Use in Children:<br />Pedexa is for adults only, it is not for use in children.<br />If you take more Pedexa than you should<br />You should not take more capsules than your doctor tells you to. If you take too many capsules contact your doctor, pharmacist or hospital and take your medicine with you.<br />If you forget to take Pedexa<br />If you forget to take a capsule, take it as soon as you remember. Do not take a double dose to make up for forgotten dose.<br />If you stop taking Pedexa<br />Suddenly stopping your treatment with Pedexa may lead to your symptoms getting worse. Do not stop taking Pedexa unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Pedexa can have side-effects, although not everybody gets them.<br />The side effects listed below were observed in arthritis patients who took celecoxib. Side effects marked with an asterisk (*) are listed below at the higher frequencies<br />that occurred in patients who took celecoxib to prevent colon polyps. Patients in these studies took celecoxib at high doses and for a long duration.<br />If any of the following happen, stop taking Pedexa and tell your doctor immediately:<br />If you have:<br />&minus; an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing<br />&minus; heart problems such as pain in the chest<br />&minus; severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or bloodstained stools, or vomiting blood<br />&minus; a skin reaction such as rash, blistering or peeling of the skin<br />&minus; liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the whites of your eyes look yellow)).<br />Very common: may affect more than 1 in 10 people:<br />&minus; High blood pressure, including worsening of existing high blood pressure*<br />Common: may affect up to 1 in 10 people:<br />&minus; Heart attack*<br />&minus; Fluid build up with swollen ankles, legs and/or hands<br />&minus; Urinary infections<br />&minus; Shortness of breath*, sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses), blocked or runny nose, sore throat, coughs, colds, flu-like symptoms<br />&minus; Dizziness, difficulty sleeping<br />&minus; Vomiting*, stomach ache, diarrhoea, indigestion, wind<br />&minus; Rash, itching<br />&minus; Muscle stiffness<br />&minus; Difficulty swallowing*<br />&minus; Headache<br />&minus; Nausea (feeling sick)<br />&minus; Painful joints<br />&minus; Worsening of existing allergies<br />&minus; Accidental injury<br />Uncommon: may affect up to 1 in 100 people:<br />&minus; Stroke*<br />&minus; Heart failure, palpitations (awareness of heart beat), fast heart rate<br />&minus; Abnormalities in liver-related blood tests<br />&minus; Abnormalities in kidney-related blood tests<br />&minus; Anaemia (changes in red blood cells that can cause fatigue and breathlessness)<br />&minus; Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles)<br />&minus; High levels of potassium in blood test results (can cause nausea (feeling sick), fatigue, muscle weakness or palpitations)<br />&minus; Impaired or blurred vision, ringing in the ears, mouth pain and sores, difficulty hearing*<br />&minus; Constipation, burping, stomach inflammation (indigestion, stomach ache or vomiting), worsening of inflammation of the stomach or intestine<br />&minus; Leg cramps<br />&minus; Raised itchy rash (hives)<br />&minus; Eye inflammation<br />&minus; Difficulty breathing<br />&minus; Skin discoloration (bruising)<br />&minus; Chest pain (generalized pain not related to the heart)<br />&minus; Face swelling<br />Rare: may affect up to 1 in 1000 people:<br />&minus; Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause stomach ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of the gullet (can cause difficulty in swallowing), inflammation of the pancreas (can lead to stomach pain)<br />&minus; Low levels of sodium in the blood (a condition known as hyponatraemia)<br />&minus; Reduced number of white blood cells (which help protect the body from infection) and blood platelets (increased chance of bleeding or bruising)<br />&minus; Difficulty coordinating muscular movements<br />&minus; Feeling confused, changes in the way things taste<br />&minus; Increased sensitivity to light<br />&minus; Loss of hair<br />&minus; Hallucinations<br />&minus; Bleeding in the eye<br />&minus; Acute reaction that may lead to lung inflammation<br />&minus; Irregular heartbeat<br />&minus; Flushing<br />&minus; Blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp pains when you breathe or collapse.<br />&minus; Bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the intestine or colon.<br />&minus; Severe liver inflammation (hepatitis). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills.<br />&minus; Acute kidney failure<br />&minus; Menstrual disturbances.<br />&minus; Swelling of the face, lips, mouth, tongue or throat, or difficulty swallowing.<br />Very rare: may affect up to 1 in 10,000 people<br />- Serious allergic reactions (including potentially fatal anaphylactic shock)<br />- Serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis and toxic epidermal necrolysis (can cause rash, blistering or peeling of<br />the skin) and acute generalised exanthematous pustulosis (symptoms include the skin becoming red with swollen areas covered in numerous small pustules)<br />- A delayed allergic reaction with possible symptoms such as rash, swelling of the face, fever, swollen glands, and abnormal test results (e.g., liver, blood cell (eosinophilia, a type of raised white blood cell count))<br />- Bleeding within the brain causing death.<br />- Meningitis (inflammation of the membrane around the brain and spinal cord).<br />- Liver failure, liver damage and severe liver inflammation (fulminant hepatitis) (sometimes fatal or requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills.<br />- Liver problems (such as cholestasis and cholestatic hepatitis, which may be accompanied by symptoms such as discoloured stools, nausea and yellowing of the skin or eyes).<br />- Inflammation of the kidneys and other kidney problems (such as nephrotic syndrome and minimal change disease, which may be accompanied by symptoms such as water retention (oedema), foamy urine, fatigue and a loss of appetite).<br />- Worsening of epilepsy (possible more frequent and/or severe seizures)<br />- Blockage of an artery or vein in the eye leading to partial or complete loss of vision.<br />- Inflamed blood vessels (can cause fever, aches, purple blotches on the skin).<br />- A reduction in the number of red and white blood cells and platelets (may cause tiredness, easy bruising, frequent nose bleeds and increased risk of infections).<br />- Muscle pain and weakness.<br />- Impaired sense of smell<br />- Loss of taste<br />Not known: frequency cannot be estimated from the available data:<br />- Decreased fertility in females, which is usually reversible on discontinuation of the medicine<br />In patients who were treated with celecoxib not for arthritis or other arthritic conditions, at doses of 400mg per day for up to 3 years, the following additional side effects have been observed:<br />Common: may affect to 1 in 10 people:<br />&minus; Heart problems: angina (chest pain)<br />&minus; Stomach problems: irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion, wind)<br />&minus; Kidney stones (which may lead to stomach or back pain, blood in urine), difficulty passing urine<br />&minus; Weight gain<br />Uncommon: may affect up to 1 in 100 people:<br />&minus; Deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of the calf or breathing problems)<br />&minus; Stomach problems: stomach infection (which can cause irritation and ulcers of the stomach and intestines)<br />&minus; Lower limb fracture<br />&minus; Shingles, skin infection, eczema (dry itchy rash), pneumonia (chest infection (possible cough, fever, difficulty breathing))<br />&minus; Floaters in the eye causing blurred or impaired vision, vertigo due to inner ear troubles, sore, inflamed or bleeding gums, mouth sores<br />&minus; Excessive urination at night, bleeding from piles/ haemorrhoids, frequent bowel movements<br />&minus; Fatty lumps in skin or elsewhere, ganglion cyst (harmless swellings on or around joints and tendons in the hand or foot), difficulty speaking, abnormal or very heavy bleeding from the vagina, breast pain<br />&minus; High levels of sodium in blood test results<br />If any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use Pedexa after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pedexa capsule contains 100 mg or 200 mg Celecoxib.<br />Inactive ingredients: lactose monohydrate, croscarmellose sodium, sodium lauryl sulfate, povidone, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pedexa 100 mg capsules are yellow opaque body printed (CAP005) and brown opaque cap printed (DAD).
Pedexa 200 mg capsules are yellow opaque body printed (CAP006) and brown opaque cap printed (DAD)
Pedexa 100 mg capsules are available in packs of 20 capsules (2 blisters of 10).
Pedexa 200 mg capsules are available in packs of 10 capsules (one blister of 10) and 30 capsules (3 blisters of 10).
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd. (Na&#39;ur - Jordan)<br />Tel. (+962 6) 57 27 132<br />Fax. (+962 6) 57 27 776</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یستخدم بیدیكسا في تخفیف العلامات والأع ا رض المصاحبة لإلتهاب المفاصل الروماتویدي،<br />إلتهاب المفاصل وإلتهاب الفقار اللاصق.<br />ینتمي بیدیكسا إلى مجموعة الأدویة الطبیة التي تسمى بمضادات الإلتهابات غیر<br />الستیرویدیة، وبشكل خاص المجموعة الفرعیة منها والتي تسمى بمثبطات إنزیمات الأكسدة<br />الحلقیة - 2. یقوم الجسم بتصنیع البروستاغلاندین المسبب للألم والإلتهاب. یقوم الجسم<br />بتصنیع المزید منها في الحالات مثل إلتهاب المفاصل الروماتویدي وإلتهاب المفاصل. یعمل<br />بیدیكسا على تقلیل إنتاج البروستاغلاندین وبالتالي تقلل من الألم والإلتهاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب أن یقوم طبیبك بوصف بیدیكسا. سوف تساعد المعلومات التالیة على حصولك على<br />أفضل النتائج عند تناول بیدیكسا. إذا كان لدیك المزید من الأسئلة إستشر طبیبك أو<br />الصیدلي.<br />موانع استعمال بیدیكسا<br />في حال حدوث أي مما یلي أخبر طبیبك حیث أنك لا تقوم بتناول بیدیكسا.<br />&bull; إذا حدث لدیك فرط في الحساسیة تجاه سیلیكوكسیب أو أي من المكونات الأخرى في<br />بیدیكسا<br />&bull; إذا حدثت لدیك تفاعلات حساسیة تجاه مجموعة الأدویة التي تسمى ب &quot;سلفونامیدات&quot;<br />(مثل بعض المضادات الحیویة التي تستخدم لعلاج العدوى)<br />&bull; إذا كنت تعاني في الوقت الحالي من قرحة في المعدة أو الأمعاء، أو نزیف في المعدة<br />أو الأمعاء<br />&bull; إذا حدث لدیك ربو، سلائل أنفیة، إحتقان شدید في الأنف، أو تفاعلات حساسیة مثل<br />طفح جلدي مع حكة، إنتفاخ في الوجه، الشفاه، اللسان أو الحلق، صعوبة في التنفس<br />أو أزیر نتیجة تناول حمض أسیتیل السالیسیلیك أو الأدویة الأخرى المضادة للإلتهاب<br />أو التي تعمل على تخفیف الألم<br />&bull; إذا كنت حاملا. في حال وجود إمكانیة لحدوث حمل خلال فترة العلاج یجب أن<br />تناقشي طرق منع الحمل مع طبیبك.<br />&bull; الرضاعة الطبیعیة<br />&bull; أم ا رض شدیدة في الكبد<br />&bull; أم ا رض شدیدة في الكلى<br />&bull; أم ا رض إلتهاب الأمعاء مثل إلتهاب القولون التقرحي أو مرض كرون<br />&bull; إذ ا كنت تعان ي م ن قصور في القلب، نقص في ترویة القلب معروف، أو مرض<br />دماغي وعائي، على سبیل المثال إذا تم تشخیص وجود نوبة قلبیة، سكتة دماغیة، أو<br />نقص ترویة مؤقت (إنخفاض مؤقت في تدفق الدم إلى الدماغ ویعرف أیضا ب السكتة<br />الدماغیة المصغرة)، ذبحة صدریة أو إنسداد في الأوعیة الدمویة التي تؤدي إلى القلب<br />أو الدماغ<br />&bull; وجود أو سبق حدوث مشاكل في الأوعیة الدمویة (مرض الش ا ریین الطرفیة) أو<br />إج ا رء عملیة ج ا رحیة في الش ا ریین الموجودة في الساقین<br />الاحتیاطات عند استعمال بیدیكسا<br />تحدث الى طبیبك أو الصیدلي قبل تناول بیدیكسا :<br />&bull; إذا سبق حدوث قرحة أو نزیف في المعدة أو الأمعاء. (لا یجب أن تتناول بیدیكسا<br />إذا كان لدیك حالیا قرحة أو نزیف في المعدة أو الأمعاء)<br />&bull; اذا كنت تتناول حمض أسیتیل السالیسیلیك (حتى في حال تناول جرعات صغیرة<br />بغرض حمایة القلب)<br />&bull; اذا كنت تتناول أدویة لتقلیل تجلط الدم (مثل الوارفارین/ مضادات التخثر شبیهة<br />الوارفارین أو مضادات التخثر الفمویة الجدیدة، مثل ابیكسابان)<br />&bull; اذا كنت تتناول أدویة تسمى كورتیكوستیروید (مثل بریدنیزون).<br />&bull; اذا كنت تتناول بیدیكسا بالت ا زمن مع مضادات الإلتهابات غیر الستیرویدیة الأخرى<br />التي لا تحتوي على حمض أسیتیل السالیسیلیك مثل ای وبروفین أو دیكلوفیناك. یجب<br />تجنب إستخدام هذه الأدویة بالت ا زمن<br />&bull; إذا كنت مدخنا، تعاني من مرض السكري، إرتفاع ضغط الدم أو إرتفاع<br />الكولیستیرول<br />&bull; إذا كان كل من القلب، الكبد أو الكلى لا یعمل بطریقة جیدة قد یقوم طبیبك بإج ا رء<br />م ا رقبة منتظمة لك<br />&bull; اذا كنت تعاني من إحتباس في السوائل (مثل إنتفاخ الكاحل و القدم)<br />&bull; اذا كنت تعاني من نقص في السوائل على سبیل المثال تقیؤ، إسهال أو إستخدام<br />مد ا رت البول (لعلاج فرط السوائل في الجسم)<br />&bull; إذا كنت تعاني من تفاعلات حساسیة خطیرة أو تفاعلات جلدیة خطیرة ناتجة عن<br />أي دواء<br />&bull; إذا أحسست بتوعك نتیجة حدوث عدوى أو إعتقدت وجود عدوى حیث أن بیدیكسا<br />قد یخفي الحمى أو العلامات الأخرى المصاحبة للعدوى أو الإلتهاب<br />&bull; إذا تجاوز عمرك 65 عاما قد یقوم الطبیب بم ا رقبة حالتك بشكل منتظم.<br />&bull; قد یزید استهلاك الكحول ومضادات الالتهابات غیر الستیرویدیة من خطر مشاكل<br />الجهاز الهضمي.<br />شأنه شأن مضادات الإلتهابات غیر الستیرویدیة الأخرى (مثل ایبوبروفین أو دیكلوفیناك) قد<br />یسبب هذا الدواء زیادة في ضغط الدم لذلك قد یطلب طبیبك إج ا رء فحص منتظم لضغط<br />الدم لدیك.<br />تم الإبلاغ عن حدوث بعض حالات تفاعل الكبد الشدیدة، والتي تتضمن إلتهاب الكبد<br />الشدید، تلف الكبد، فشل الكبد (قد تؤدي إلى الوفاة أو تحتاج لز ا رعة الكبد) مع إستخدام<br />سیلیكوكسیب.<br />في الحالات التي تم الإبلاغ عن بدء التأثیر، تحدث معظم تفاعلات الكبد الشدیدة خلال<br />شهر واحد من بدء فترة العلاج.<br />قد یزید بیدیكسا م ن صعوب ة حدوث حمل . یج ب أ ن تخبري طبیب ك إذا كنت تخططین<br />لحدوث حمل أو في حال وجود مشكلة في حدوث حمل.<br />التداخلات الدوائیة من أخذ هذا المستحضر مع أي أدویة أخرى أو أعشاب أو مكملات<br />غذائیة<br />أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخ ا ر أو قد تتناول أي أدویة أخرى.<br />&bull; دیكسترومیتورفان (تستخدم لعلاج السعال)<br />&bull; مثبطات الإنزیم المحول للأنجیوتنسین ، او مناهضات للأنجیوتنسین- 2، حاص ا رت<br />بیتا ومد ا رت البول (یستخدم لإرتفاع ضغط الدم وفشل القلب)<br />&bull; فلوكونازول وریفامبیسین (یستخدم لعلاج الإلتهابات البكتیریة والفطریة)<br />&bull; وارفارین أو أدویة أخرى شبیهة بالوارفارین (المواد &quot;الممیعة للدم&quot; التي تقلل من تخثر<br />الدم)، تشمل أدویة جدیدة مثل ابیكسابان.<br />&bull; اللیثیوم (تستخدم لعلاج بعض أنواع الإكتئاب)<br />&bull; الأدویة الأخرى التي تستخدم لعلاج الإكتئاب، إضط ا ربات النوم، إرتفاع ضغط الدم<br />أو عدم إنتظام معدل ضربات القلب<br />&bull; مضادات الذهان (تستخدم لعلاج بعض الإضط ا ربات العقلیة)<br />&bull; میثوت ریكسات (یستخدم لعلاج إلتهاب المفاصل الروماتویدي ، الصدفیة وسرطان<br />الدم)<br />&bull; كاربامازیبین (تستخدم لعلاج الصرع / النوبات وبعض أشكال الألم أو الإكتئاب)<br />&bull; باربیتو ا رت (تستخدم لعلاج الصرع / النوبات وبعض إضط ا ربات النوم)<br />&bull; سیكلوسبورین وتاكرولیموس (التي تستخدم لكبت جهاز المناعة بعد ز ا رعة<br />الأعضاء)<br />یمكن تناول جرعة منخفضة من بیدیكسا مع حمض أسیتیل السالیسیلیك ( 75 ملغم أو أقل<br />یومیا). إسأل طبیبك للحصول على المشورة قبل تناول الأدویة معا.<br />الحمل والرضاعة<br />اذا كنت حامل او مرضع، تعتقدین بأنك حامل او تخططین لحدوث حمل، اطلبي استشارة<br />طبیبك او الصیدلي قبل تناول هذا الدواء.<br />الحمل<br />یجب عدم استخدام بیدیكسا لدى النساء الحوامل أو اللاتي یخططن للحمل (على سبیل<br />المثال النساء اللواتي لدیهن القدرة عل ى الإنجا ب ولا یقمن بإستخدام وسائل كافیة لمنع<br />الحمل) خلال إستم ا رر العلاج. في حال حدوث حمل خلال العلاج مع تناول بیدیكسا یجب<br />التوقف عن العلاج والتحدث مع طبیبك للحصول على علاج بدیل.<br />الرضاعة<br />یمنع استخدام بیدیكسا خلال الرضاعة.<br />الخصوبة<br />قد تجعل مضادات الإلتهابات غیر الستیرویدیة، من ضمنها بیدیكسا، الحمل أكثر صعوبة.<br />یجب علیك اخبار الطبیب اذا كنت تخططی ن للحمل أ و في حال كان لدیك صعوبة في<br />حدوث الحمل.<br />تأثیر بیدیكسا على القیادة وإستخدام الآلات<br />یجب أن تتنبه لتأثیر بیدیكسا علیك قبل القیادة أو تشغیل الآلات. إذا شعرت بدوار أو نعاس<br />بعد تناول بیدیكسا، لا یجب أن تقود أو تشغل الآلات حتى زوال التأثیر.<br />معلومات هامة حول بعض مكونات بیدیكسا<br />تحتوي كبسولات بیدیكسا على لاكتوز، اذا تم إخبارك من قبل الطبیب أنك غیر قادر على<br />تحمل بعض أنواع السكریات، إسأل طبیبك قبل تناول هذه المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب علیك دائماً أن تتناول بیدیكسا تماما كما أخبرك الطبیب أو الصیدلي. یجب أن تسأل<br />طبیبك أو الصیدلي إذا لم تكن متأكدا. إذا كنت تعتقد أو تشعر أن تأثیر الدواء قوي جدا أو<br />ضعیف جدا تحدث مع طبیبك أو الصیدلي.<br />سوف یقوم طبیبك بتحدید الجرعة التي یجب أن تقوم بتناولها. بما أن خطر حدوث<br />الأع ا رض الجانبیة قد یرتبط بحدوث مشاكل في القلب مع زیادة الجرعة أو فترة العلاج، من<br />المهم أن تقوم بإستخدام أقل جرعة ممكنة للسیطرة على الألم ویجب أن لا تقوم بتناول<br />بیدیكسا لفترة أطول من التي تحتاج إلیها للسیطرة على الأع ا رض.<br />طریقة الاستخدام<br />یتم تناول بیدیكسا عن طریق الفم. یمكن تناول الكبسولات في أي وقت خلال الیوم، مع أو<br />بدون تناول الطعام. مع ذلك یجب محاولة تناول جرعة بیدیكسا بنفس الوقت یومیا.<br />اذا كان لدیك صعوبة في بلع الكبسولات: یمكن رش محتویات الكبسولة كاملة على ملعقة<br />شاي تحتوي على طعام شبه صلب مستوي السطح (مثل صلصة التفاح الباردة أو على<br />درجة ح ا ررة الغرفة، عصیدة الأرز، لبن أو موز مهروس) وبلعه فو ا رً مع شرب تقریباً 240<br />مل من الماء.<br />لفتح الكبسولة، أمسك الكبسولة بشكل مستقیم لجمع الحبیبات في الجزء السفلي ثم اضغط<br />على الغطاء الأعلى وقم بلفه لإ ا زلته، كن حذر بعدم سكب المحتویات. لا تمضغ أو تسحق<br />الحبیبات.<br />تحدث مع طبیبك خلال أسبوعین من بدء العلاج إذا لم تحصل على الفائدة.<br />الجرعة الموصى بها هي:<br />لعلاج إلتهاب المفاصل الجرعة الموصى بها هي 200 ملغم یومیا، یتم زیادة الجرعة من<br />قبل طبیبك إلى الجرعة القصوى وهي 400 ملغم عند الحاجة.<br />الجرعة المعتادة هي:<br />&bull; كبسولة واحدة 200 ملغم مرة واحدة یومیا؛ أو<br />&bull; كبسولة واحدة 100 ملغم مرتین یومیا.<br />لعلاج إلتهاب المفاصل الروماتویدي الجرعة الموصى بها هي 200 ملغم یومیا، یتم زیادة<br />الجرعة من قبل طبیبك إلى الجرعة القصوى وهي 400 ملغم عند الحاجة.<br />الجرعة المعتادة هي:<br />&bull; كبسولة واحدة 100 ملغم مرتین یومیا.<br />لعلاج إلتهاب الفقار اللاصق الجرعة الموصى بها هي 200 ملغم یومیا، یتم زیادة الجرعة<br />من قبل طبیبك إلى الجرعة القصوى وهي 400 ملغم عند الحاجة.<br />الجرعة المعتادة هي:<br />&bull; كبسولة واحدة 200 ملغم مرة واحدة یومیا؛ أو<br />&bull; كبسولة واحدة 100 ملغم مرتین یومیا.<br />مشاكل الكلى أو الكبد: یجب أن تتأكد من معرفة طبیبك وجود مشاكل في الكبد أو الكلى<br />حیث أنك قد تحتاج إلى جرعة أقل.<br />كبار السن، خاصة الذین تقل أو ا زنهم عن 50 كغم: إذا كان عمرك یزید عن 65 عام<br />وخاصة إذا كان وزنك یقل عن 50 كغم، قد یرغب طبیبك في م ا رقبتك عن كثب.<br />یجب أن لا تأخذ أكثر من 400 ملغم یومیا.<br />الاستخدام في الاطفال<br />یتم إعطاء بیدیكسا للكبار فقط، یمنع إستخدامه للأطفال.<br />الجرعة ال ا زئدة من بیدیكسا<br />یجب أن لا تتناول أكثر من الجرعة التي وصفها الطبیب. إذا تناولت جرعة ا زئدة تحدث مع<br />طبیبك، الصیدلي أو المستشفى ویجب أن تأخذ الدواء الذي تناولته معك.<br />نسیان تناول جرعة بیدیكسا<br />إذا نسیت تناول كبسولة، یجب أن تقوم بتناولها فور تذكرها. یجب أن لا تقوم بمضاعفة<br />الجرعة لتعویض الجرعة الفائتة.<br />التوقف عن تناول بیدیكسا<br />قد یسبب التوقف المفاجئ عن تناول علاج بیدیكسا إلى تفاقم الأع ا رض. لا تتوقف عن<br />تناول بیدیكسا إلا إذا أخبرك طبیبك بذلك. قد یخبرك طیببك بتقلیل الجرعة لعدة أیام قبل<br />التوقف عن تناول الدواء بشكل كامل.<br />اذا كان لدیك اي اسئلة اضافیة حول استخدام هذا الدواء، اسأل طبیبك او الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن الأدویة الأخرى قد یسبب بیدیكسا أع ا رضا جانبیة على الرغم من عدم حدوثها مع<br />جمیع المرضى.<br />تم سرد الأع ا رض الجانبیة التي تم الإبلاغ عن حدوثها أدناه في مرضى إلتهاب المفاصل في<br />المرضى الذین یتناولون سیلیكوكسیب. تم تمییز الأع ا رض الجانبیة التي تحدث بشكل أكثر<br />تك ا رر أدناه بنجمة (*) والتي تحدث للمرضى الذین یقومون بتناول سیلیكوكسیب لمنع حدو ث<br />از ا رم حمیدة في القولون. تم إعطاء جرعات كبیرة لفترة طویلة الأمد للمرضى الذین أجریت<br />علیهم الد ا رسات.<br />توقف عن تناول بیدیكسا وأخبر طبیبك على الفور في حال حدوث أي مما یلي:<br />إذا حدث لدیك:<br />&minus; تفاعلات حساسیة مثل طفح جلدي، تورم في الوجه، أزیر أو صعوبة في التنفس<br />&minus; مشاكل في القلب مثل ألم في الصدر<br />&minus; ألم شدید في المعدة أو أي علامة على حدوث نزیف في المعدة أو الأمعاء، مثل ب ا رز<br />أسود أو مصحوب بالدم، أو قيء یحتوي على دم<br />&minus; تفاعلات جلدیة مثل طفح، تقرح أو تقشر الجلد<br />&minus; فشل الكبد (قد تتضمن الأع ا رض حدوث غثیان، إسهال، یرقان (إصف ا رر في الجلد أو<br />في بیاض العیون)<br />شائع جدا: قد تؤثر على أكثر من 1 من بین 10 أشخاص:<br />&minus; إرتفاع ضغط الدم، تشمل تفاقم ارتفاع ضغط الدم لدى المرضى المصابین به*.<br />شائع: قد تؤثر كحد أقصى على 1 من بین 10 أشخاص:<br />&minus; نوبة قلبیة*<br />&minus; ت ا ركم السوائل مع إنتفاخ الكاحل، القدمین و/أو الیدین<br />&minus; عدوى في الجهاز البولي<br />&minus; ضیق التنفس*، إلتهاب الجیوب الأنفیة (إلتهاب الجیوب الأنفیة، عدوى في الجیوب<br />الأنفیة، إنسداد أو ألم في الجیوب الأنفیة)، إنسداد أو سیلان في الأنف، إلتهاب<br />الحلق، سعال، برد، أع ا رض تشبه الإنفلون ا ز<br />&minus; دوار، صعوبة في النوم<br />&minus; قيء*، ألم في المعدة، إسهال، عسر الهضم، ریح<br />&minus; طفح، حكة<br />&minus; تیبس العضلات<br />&minus; صعوبة في البلع*<br />&minus; صداع<br />&minus; غثیان<br />&minus; الم في المفاصل<br />&minus; تفاقم في الحساسیة الموجودة سابقا<br />&minus; إصابة عرضیة<br />غیر شائع: تؤثر كحد أقصى على 1 من بین 100 شخص:<br />&minus; سكتة دماغیة*<br />&minus; فشل في القلب، خفقان (الشعور بنبضات القلب)، تسارع معدل ضربات القلب<br />&minus; إختلال في فحوصات الدم المرتبطة في الكبد<br />&minus; إختلال في فحوصات الدم المرتبطة في الكلى<br />&minus; فقر دم (تغیر في كریات الدم الحم ا رء التي من الممكن أن تسبب تعب وضیق التنفس)<br />&minus; قلق، إكتئاب، تعب، نعاس، الاحساس ب وخز (شبیه بالإبر والدبابیس)<br />&minus; إرتفاع مستوى البوتاسیوم الذي یظهر في فحوصات الدم (یسبب حدوث غثیان، تعب،<br />إجهاد عضلي أو خفقان)<br />&minus; خلل أو عدم وضوح الرؤیة، طنی ن ف ي الأذن ، أل م وتقرحات في الفم ، صعوب ة في<br />السمع*<br />&minus; إمساك، تجشؤ، إلتهاب المعدة (عسر الهضم، ألم في المعدة أو قيء)، تفاقم في<br />إلتهاب المعدة أو الأمعاء<br />&minus; تشنج القدم<br />&minus; طفح جلدي ظاهر (شرى)<br />&minus; التهاب العین<br />&minus; صعوبة في التنفس<br />&minus; تلون الجلد (كدمات)<br />&minus; ألم في الصدر (ألم عام لیس له علاقة بالقلب)<br />&minus; انتفاخ الوجه<br />نادر: قد تؤثر كحد أقصى على 1 من بین 1000 شخص:<br />&minus; قرحة (نزیف) في المعدة، المريء أو الأمعاء، أو تمزق في الأمعاء (من الممكن أن<br />تسبب ألم في المعدة، حمى، غثیان، قيء، إنسداد في الأمعاء)، ب ا رز لونه أسود أو<br />غامق، إلتهاب المريء (من الممكن أن تسبب صعوبة في البلع)، إلتهاب البنكریاس<br />(قد تؤدي إلى ألم في المعدة)<br />&minus; انخفاض في مستویات الصودیوم في الدم<br />&minus; إنخفاض في عدد كریات الدم البیضاء (تساعد على حمایة الجسم من العدوى)<br />والصفائح الدمویة (زیادة إحتمالیة حدوث نزف أو كدمات)<br />&minus; صعوبة في تنسیق حركة العضلات<br />&minus; الشعور بإرتباك، تغیر في حاسة التذوق<br />&minus; زیادة الحساسیة تجاه الضوء<br />&minus; تساقط الشعر<br />&minus; هلوسات<br />&minus; نزیف في العین<br />&minus; رد فعل حاد والذي قد یؤدي الى التهاب في الرئة<br />&minus; عدم انتظام ضربات القلب<br />&minus; تورّد وتوهج الوجنتین<br />&minus; تجلط الدم في الأوعیة الدمویة في الرئتین. قد تشمل الأع ا رض ضیق مفاجئ في<br />التنفس، آلام حادة عند التنفس أو انهیار.<br />&minus; نزیف في المعدة أو الأمعاء (یؤدي الى ب ا رز مصحوب بالدم أو قيء)، التهاب في<br />الأمعاء أو القولون.<br />&minus; التهاب الكبد الشدید. قد تشمل الأع ا رض غثیان، اسهال، یرقان (تلون في الجلد أو<br />العینین باللون الأصفر)، بول داكن، ب ا رز باهت، النزف بسهولة، حكة أو قشعریرة.<br />&minus; فشل كلوي حاد<br />&minus; اضط ا ربات الحیض<br />&minus; انتفاخ في الوجه، أو الشفاه، أو الفم، أو اللسان، أو الحلق أو صعوبة في البلع.<br />نادر جداً: قد تؤثر كحد أقصى على 1 من بین 10000 شخص:<br />&minus; تفاعلات حساسیة خطیرة (تتضمن صدمة تأقیة مع إمكانیة التسبب بالوفاة)<br />&minus; حالات جلدیة خطیرة مثل متلازمة ستیفن جونسون، إلتهاب الجلد التقشري وإنحلال<br />البشرة السمي (قد یسبب طفح جلدي، تقرح أو تقشر الجلد) و طفح بث ري ظاهر حاد<br />یعم الجسم (الأع ا رض تشمل مناطق منتفخة حم ا رء مع العدید من البث ا رت الصغیرة)<br />&minus; تفاعلات حساسیة متأخرة مع أع ا رض محتملة مثل طفح، إنتفاخ في الوجه، حمى،<br />إنتفاخ في الغدد ، ونتائج غیر طبیعیة (على سبیل المثال الكبد، خلایا الدم، (كثرة<br />الحمضات، زیادة تعداد خلایا الدم البیضاء)<br />&minus; نزیف في الدماغ یسبب الوفاة<br />&minus; إلتهاب السحایا (إلتهاب في الغشاء الذي یحیط بالدماغ أو النخاع الشوكي)<br />&minus; فشل الكبد، تلف الكبد وإلتهاب شدید في الكبد (قد یسبب الوفاة أو یحتاج إلى ز ا رعة<br />الكبد بعض الأحیان). قد تتضمن الأع ا رض حدوث غثیان، إسهال، یرقان (إصف ا رر<br />الجلد أو العیون)، بول داكن، ب ا رز باهت، سهولة حدوث نزیف، حكة أو قشعریرة<br />&minus; مشاكل في الكبد (مثل ركود صف ا روي والتهاب الكبد الركودي، والتي قد تكون مصاحبة<br />بأع ا رض مثل تلون في الب ا رز،غثیان، واصف ا رر الجلد أو العینین)<br />&minus; التهاب الكلى ومشاكل أخرى للكلیة (مثل المتلازمة الكلویة والتهاب طفیف في<br />الكبیبات، والتي قد تكون مصحوبة بالأع ا رض مثل احتباس الماء (وذمة)، بول رغوي،<br />تعب وفقدان الشهیة).<br />&minus; تفاقم في الصرع (قد تسبب نوبات صرع أكثر تك ا رر و/أو شدة)<br />&minus; إنسداد في الشریان أو الأوردة في العین مما یتسبب بحدوث فقدان جزئي أو كلي في<br />الرؤیة .<br />&minus; إلتهاب الأوعیة الدمویة (تسبب بحدوث حمى، آلام، بقع أرجوانیة على الجلد)<br />&minus; إنخفاض عدد خلایا الدم الحم ا رء والبیضاء والصفائح الدمویة (قد تسبب حدوث تعب،<br />سهولة حدوث كدمات، نزیف متكرر في الأنف وزیادة خطر حدوث عدوى)<br />&minus; ألم وضعف في العضلات.<br />&minus; إختلال في حاسة الشم<br />&minus; فقدان حاسة التذوق<br />غیر معروف: التك ا رر لا یمكن تقدیره من البیانات المتاحة:<br />&minus; انخفاض الخصوبة لدى الإناث، ویكون عكوس عادةً عند التوقف عن تناول الدواء.<br />عند تناول سیلیكوكسیب لعلاج إلتهاب المفاصل وحالات أخرى متعلقة بإلتهاب المفاصل<br />بجرعة 400 ملغم یومیا لمدة 3 سنوات، تم الإبلاغ عن حدوث الأع ا رض الجانبیة الإضافیة<br />التالیة:<br />شائع: قد تؤثر كحد أقصى على 1 من بین 10 أشخاص:<br />&minus; مشاكل في القلب: ذبحة صدریة (ألم في الصدر)<br />&minus; مشاكل في المعدة: متلازمة القولون المتهیج (تتضمن حدوث ألم في المعدة، إسهال،<br />عسر الهضم، ریح)<br />&minus; حصى الكلى (من الممكن أن تؤدي إلى ألم في المعدة أو الظهر، دم في البول)،<br />صعوبة في تمریر البول<br />&minus; زیادة في الوزن<br />غیر شائع: قد تؤثر كحد أقصى على 1 من بین 100 شخص:<br />&minus; تجلط وریدي عمیق (تجلط الدم عادة في القدم والذي من الممكن أن یسبب ألم، إنتفاخ<br />أو إحم ا رر في الساق أو مشاكل في التنفس)<br />&minus; مشاكل في المعدة: عدوى في المعدة (والذي من الممكن أن یسبب تهیج وقرحة في<br />المعدة و الأمعاء)<br />&minus; كسر في الأط ا رف السفلیة<br />&minus; هربس نطاقي، عدوى في الجلد، إكزیما (طفح جاف مع حكة)، إلتهاب رئوي (عدوى<br />في الصدر (قد یحدث سعال، حمى، صعوبة في التنفس))<br />&minus; عوائم في العین تسبب عدم وضوح أو خلل في الرؤیة، دوخة نتیجة حدوث مشاكل في<br />الأذن الداخلیة، قرحة، إلتهاب أو نزف في اللثة، تقرحات في الفم<br />&minus; تبول مفرط أثناء اللیل، نزیف بسبب البواسیر، حركات متكررة في الأمعاء<br />&minus; كتل دهنیة في الجلد أو في أماكن أخرى، كیس عقدي (إنتفاخ حمید في أو حول<br />المفاصل والأوتار في الید أو القدم)، صعوبة في الكلام، نزف غیر طبیعي أو غزیر<br />جدا من المهبل، ألم في الثدي<br />&minus; إرتفاع مستوى الصودیوم في الدم التي تظهر في نتائج فحوصات الدم<br />إذا أصبحت أي من الأع ا رض الجانبیة شدیدة، أو إذا لاحظت وجود أي أع ا رض جانبیة غیر<br />مذكورة في هذه النشرة، أخبر طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; یحفظ بیدیكسا بعیدا عن متناول ایدي الاطفال و نظرهم.<br />&bull; لا تستخدم بیدیكسا بعد تاریخ الانتهاء المذكور على العبوة الخارجیة. یدل تاریخ<br />الانتهاء على اخر یوم في الشهر المذكور.<br />&bull; یحفظ على درجة ح ا ررة لا تزید عن 30 درجة مئویة.<br />&bull; لا تتخلص من الأدویة في المیاه العادمة أو النفایات المنزلیة. إسأل الصیدلي حول<br />الطریقة السلیمة للتخلص من الأدویة التي لم تعد بحاجة إلیها. سیساعد هذا في<br />حمایة البیئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تحتوي كل كبسولة بیدیكسا على 100 ملغم أو 200 ملغم سیلیكوكسیب.<br />المواد غیر الفعالة: لاكتوز أحادي الماء، كروس كارمیلوس صودیوم، ملح الصودیوم للوریل<br />السلفات، بوفیدون، ستیا ا رت المغنیسیوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>بیدیكسا 100 ملغم كبسولات حیث جسم الكبسولة اصفر اللون غیر شفاف مطبوع علیه<br />DAD) و غطاء الكبسولة لونه بني مطبوع علیه (CAP005) .(<br />بیدیكسا 200 ملغم كبسولات حیث جسم الكبسولة اصفر اللون غیر شفاف مطبوع علیه<br />DAD) وغطاء الكبسولة لونه بني مطبوع علیه (CAP006) .(<br />تتوفر كبسولات بیدیكسا 100 ملغم في عبوات سعة كل منها 20 كبسولة (شریطین في كل<br />منها 10 كبسولات).<br />تتوفر كبسولات بیدیكسا 200 ملغم في عبوات سعة كل منها 10 كبسولات (شریط واحد من<br />.( 10 ) و 30 كبسولة ( 3 اشرطة في كل شریط 10<br />قد لا یتم تسویق جمیع احجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة دار الدواء للتنمیة والإستثمار المساهمة المحدودة (ناعور &ndash; الأردن)</p><p dir="RTL">هاتف. 132 27 57 (6 962 +)</p><p dir="RTL">فاكس.776 27 57 (6 962 +)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pedexa® Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 100 and 200 mg of celecoxib.
Excipient with known effect :Lactose.
Each Pedexa® 100 mg capsule contains 25.56 mg lactose monohydrate.
Each Pedexa® 200 mg capsule contains 51.1 mg lactose monohydrate.
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules.
Pedexa® 100 mg capsules are yellow opaque body printed (CAP005) and brown opaque cap printed (DAD).
Pedexa® 200 mg capsules are yellow opaque body printed (CAP006) and brown opaque cap printed (DAD).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pedexa&reg; is indicated in adults for the symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.<br />The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />As the cardiovascular (CV) risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).<br />Osteoarthritis<br />The usual recommended daily dose is 200 mg taken once daily or in two divided doses. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.<br />Rheumatoid arthritis<br />The initial recommended daily dose is 200 mg taken in two divided doses. The dose may, if needed, later be increased to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.<br />Ankylosing spondylitis<br />The recommended daily dose is 200 mg taken once daily or in two divided doses. In a few patients, with insufficient relief from symptoms, an increased dose of 400 mg once daily or in two divided doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.<br />The maximum recommended daily dose is 400 mg for all indications.<br />Special populations<br />Elderly (&gt;65 years)<br />As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50 kg. (see sections 4.4 and 5.2).<br />Paediatric population<br />Celecoxib is not indicated for use in children.<br />CYP2C9 poor metabolisers<br />Patients who are known, or suspected to be CYP2C9 poor metabolisers based on genotyping or previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution as the risk of dose-dependent adverse effects is increased. Consider reducing the dose to half the lowest recommended dose (see section 5.2).<br />Hepatic impairment<br />Treatment should be initiated at half the recommended dose in patients with established moderate liver impairment with a serum albumin of 25-35 g/l. Experience in such patients is limited to cirrhotic patients (see sections 4.3, 4.4 and 5.2).<br />Renal impairment<br />Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution. (see sections 4.3, 4.4 and 5.2).<br />Method of administration<br />Oral use<br />Pedexa&reg; may be taken with or without food. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce, rice gruel, yogurt or mashed banana. To do so, the entire capsule contents must be carefully emptied onto a level teaspoon of cool or room temperature applesauce, rice gruel, yogurt or mashed banana and should be ingested immediately with 240 ml of water. The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to 6 hours under refrigerated conditions (2-8&deg;C). The sprinkled capsule contents on mashed banana should not be stored under refrigerated conditions and should be ingested immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Known hypersensitivity to sulfonamides.
Active peptic ulceration or gastrointestinal (GI) bleeding.
Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid (aspirin) or other NSAIDs including COX-2 inhibitors.
In pregnancy and in women of childbearing potential unless using an effective method of contraception (see section 4.6). Celecoxib has been shown to cause malformations in the two animal species studied (see sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown, but cannot be excluded.
Breast-feeding (see sections 4.6 and 5.3).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
Patients with estimated creatinine clearance <30 ml/min.
Inflammatory bowel disease.
Congestive heart failure (NYHA II-IV).
Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastrointestinal (GI) effects<br />Upper and lower gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them resulting in fatal outcome, have occurred in patients treated with celecoxib. Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly, glucocorticoids, patients using alcohol, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.<br />There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid vs. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).<br />Concomitant NSAID use<br />The concomitant use of celecoxib and a non-aspirin NSAID should be avoided.<br />Cardiovascular effects<br />Increased number of serious cardiovascular (CV) events, mainly myocardial infarction , has been found in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with celecoxib at doses of 200 mg BID and 400 mg BID compared to placebo (see section 5.1).<br />As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. NSAIDs, including COX-2 selective inhibitors, have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term. The exact magnitude of the risk associated with a single dose has not been determined, nor has the exact duration of therapy associated with increased risk. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).<br />Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1).<br />COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore, antiplatelet therapies should not be discontinued (see section 5.1).<br />Fluid retention and oedema<br />As with other drugs known to inhibit prostaglandin synthesis, fluid retention and oedema have been observed in patients taking celecoxib. Therefore, celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.<br />Hypertension<br />As with all NSAIDS, celecoxib can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib and throughout the course of therapy.<br />Hepatic and renal effects<br />Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the elderly and therefore medically appropriate supervision should be maintained.<br />NSAIDs, including celecoxib, may cause renal toxicity. Clinical trials with celecoxib have shown renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal toxicity are<br />those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, ACE-inhibitors, angiotensin II receptor antagonists, and the elderly (see section 4.5). Such patients should be carefully monitored while receiving treatment with celecoxib.<br />Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Among the cases that reported time to onset, most of the severe adverse hepatic events developed within one month after initiation of celecoxib treatment (see section 4.8).<br />If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of celecoxib therapy should be considered.<br />CYP2D6 inhibition<br />Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated drugs that are metabolised by CYP2D6 (see section 4.5).<br />CYP2C9 poor metabolisers<br />Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).<br />Skin and systemic hypersensitivity reactions<br />Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (including anaphylaxis, angioedema and drug rash with eosinophilia and systemic symptoms (DRESS), or hypersensitivity syndrome), have been reported in patients receiving celecoxib (see section 4.8). Patients with a history of sulfonamide allergy or any drug allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section 4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.<br />General<br />Celecoxib may mask fever and other signs of inflammation.<br />Use with oral anticoagulants<br />In patients on concurrent therapy with warfarin, serious bleeding events, some of them fatal, have been reported. Increased prothrombin time (INR) with concurrent therapy has been reported. Therefore, this should be closely monitored in patients receiving warfarin/coumarin-type oral anticoagulants, particularly when therapy with celecoxib is initiated or celecoxib dose is changed (see section 4.5). Concomitant use of anticoagulants with NSAIDS may increase the risk of bleeding. Caution should be<br />exercised when combining celecoxib with warfarin or other oral anticoagulants, including novel anticoagulants (e.g. apixaban, dabigatran, and rivaroxaban).<br />Pedexa&reg; 100 mg and 200 mg capsules contain lactose, Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />Anticoagulants<br />Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications. Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with celecoxib is initiated or the dose of celecoxib is changed (see section 4.4). Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.<br />Anti-hypertensives<br />NSAIDs may reduce the effect of anti-hypertensive medicinal products including ACE-inhibitors, angiotensin II receptor antagonists, diuretics and beta-blockers. As for NSAIDs, the risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function (e.g. dehydrated patients, patients on diuretics, or elderly patients) when ACE inhibitors, angiotensin II receptor antagonists, and/or diuretics are combined with NSAIDs, including celecoxib (see section 4.4). Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.<br />In a 28-day clinical study in patients with lisinopril-controlled Stage I and II hypertension, administration of celecoxib 200 mg BID resulted in no clinically significant increases, when compared to placebo treatment, in mean daily systolic or diastolic blood pressure as determined using 24-hour ambulatory blood pressure monitoring. Among patients treated with celecoxib 200 mg BID, 48% were considered unresponsive to lisinopril at the final clinic visit (defined as either cuff diastolic blood pressure &gt;90 mmHg or cuff diastolic blood pressure increased &gt;10% compared to baseline), compared to 27% of patients treated with placebo; this difference was statistically significant.<br />Ciclosporin and Tacrolimus<br />Coadministration of NSAIDs and ciclosporin or tacrolimus may increase the nephrotoxic effect of ciclosporin or tacrolimus, respectively. Renal function should be monitored when celecoxib and any of these drugs are combined.<br />Acetylsalicylic acid<br />Celecoxib can be used with low-dose acetylsalicylic acid but is not a substitute for acetylsalicylic acid for cardiovascular prophylaxis. In the submitted studies, as with other NSAIDs, an increased risk of gastrointestinal ulceration or other gastrointestinal complications compared to use of celecoxib alone was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).<br />Pharmacokinetic interactions<br />Effects of celecoxib on other drugs<br />CYP2D6 Inhibition<br />Celecoxib is an inhibitor of CYP2D6. The plasma concentrations of drugs that are substrates of this enzyme may be increased when celecoxib is used concomitantly. Examples of drugs which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, anti-arrhythmic drugs, etc. The dose of individually dose-titrated CYP2D6 substrates may need to be reduced when treatment with celecoxib is initiated or increased if treatment with celecoxib is terminated.<br />Concomitant administration of celecoxib 200 mg twice daily resulted in 2.6-fold and 1.5-fold increases in plasma concentrations of dextromethorphan and metoprolol (CYP2D6 substrates), respectively. These increases are due to celecoxib CYP2D6 inhibition of the CYP2D6 substrate metabolism.<br />CYP2C19 Inhibition<br />In vitro studies have shown some potential for celecoxib to inhibit CYP2C19 catalysed metabolism. The clinical significance of this in vitro finding is unknown. Examples of drugs which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.<br />Methotrexate<br />In patients with rheumatoid arthritis celecoxib had no statistically significant effect on the pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses). However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two drugs.<br />Lithium<br />In healthy subjects, co-administration of celecoxib 200 mg twice daily with 450 mg twice daily of lithium resulted in a mean increase in Cmax of 16% and in AUC of 18% of lithium. Therefore, patients on lithium treatment should be closely monitored when celecoxib is introduced or withdrawn.<br />Oral contraceptives<br />In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1 mg norethisterone /35 micrograms ethinylestradiol).<br />Glibenclamide/tolbutamide<br />Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide to a clinically relevant extent.<br />Effects of other drugs on celecoxib<br />CYP2C9 Poor Metabolisers<br />In individuals who are CYP2C9 poor metabolisers and demonstrate increased systemic exposure to celecoxib, concomitant treatment with CYP2C9 inhibitors such as fluconazole could result in further increases in celecoxib exposure. Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).<br />CYP2C9 Inhibitors and Inducers<br />Since celecoxib is predominantly metabolised by CYP2C9 it should be used at half the recommended dose in patients receiving fluconazole. Concomitant use of 200 mg single dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib Cmax of 60% and in AUC of 130%. Concomitant use of inducers of CYP2C9 such as rifampicin, carbamazepine and barbiturates may reduce plasma concentrations of celecoxib.<br />Ketoconazole and Antacids<br />Ketoconazole or antacids have not been observed to affect the pharmacokinetics of celecoxib.<br />Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see sections 4.3 and 5.3). Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other drugs inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.<br />During the second or third trimester of pregnancy, NSAIDs including celecoxib may cause fetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible.<br />Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see sections 4.3 and 4.4). If a woman becomes pregnant during treatment, celecoxib should be discontinued.<br />Breast-feeding<br />Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma. Administration of celecoxib to a limited number of lactating women has shown a very low transfer of celecoxib into breast milk. Women who take celecoxib should not breastfeed.<br />Fertility<br />Based on the mechanism of action, the use of NSAIDs, including celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizziness, vertigo or somnolence while taking celecoxib should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed by system organ class and ranked by frequency in Table 1, reflecting data from the following sources:<br />&bull; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence rates greater than 0.01% and greater than those reported for placebo during 12 placebo- and/or active-controlled clinical trials of duration up to 12 weeks at celecoxib daily doses from 100 mg up to 800 mg. In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with celecoxib at daily doses up to 800 mg, including approximately 2300 patients treated for 1 year or longer. The adverse reactions observed with celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in Table 1.<br />&bull; Adverse reactions reported at incidence rates greater than placebo for subjects treated with celecoxib 400 mg daily in long-term polyp prevention trials of duration up to 3 years (the Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials; see section 5.1, Pharmacodynamic properties: Cardiovascular safety &ndash; long-term studies involving patients with sporadic adenomatous polyps).<br />&bull; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt;70 million patients were treated with celecoxib (various doses, durations, and indications). Even though these were identified as reactions from post-marketing reports, trial data<br />were consulted to estimate frequency. Frequencies are based on a cumulative meta-analysis with pooling of trials representing exposure in 38102 patients.<br />Table 1. Adverse Drug Reactions in Celecoxib Clinical Trials and Surveillance Experience (MedDRA Preferred Terms)1,2</p><table border="1" cellspacing="0" cellpadding="0" style="width:775px"><tbody><tr><td style="vertical-align:top"><p><br /><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse Drug Reaction Frequency</strong></p></td><td style="width:66px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to &lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to &lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to &lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top; width:66px"><p><strong>Frequency Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Sinusitis, upper respiratory tract infection, pharyngitis,urinary tract infection</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Leukopenia, thrombo-cytopenia</p></td><td style="vertical-align:top"><p>Pancytopenia<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyper-sensitivity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic shock<sup>4</sup>, anaphylactic reaction<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, depression, fatigue</p></td><td style="vertical-align:top"><p>Confusional state, hallucinations<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dizziness, hypertonia, headache<sup>4</sup></p></td><td style="vertical-align:top"><p>Cerebral infarction<sup>1</sup>, paraesthesia, somnolence</p></td><td style="vertical-align:top"><p>Ataxia, dysgeusia</p></td><td style="vertical-align:top"><p>Haemorrhage intracranial (including fatal intracranial haemorrhage)<sup>4</sup>, meningitis aseptic<sup>4</sup>, epilepsy (including aggravated epilepsy)<sup>4</sup>, ageusia<sup>4</sup>, anosmia<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vision blurred, conjunctivitis<sup>4</sup></p></td><td style="vertical-align:top"><p>Eye haemorrhage<sup>4</sup></p></td><td style="vertical-align:top"><p>Retinal artery occlusion<sup>4</sup>, retinal vein occlusion<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus, hypoacusis<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myocardial infarction<sup>1</sup></p></td><td style="vertical-align:top"><p>Cardiac failure, palpitations, tachycardia</p></td><td style="vertical-align:top"><p>Arrhythmia<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hyper-tension<sup>1</sup>(including aggravated hyper-tension)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pulmonary embolism<sup>4</sup>, flushing<sup>4</sup></p></td><td style="vertical-align:top"><p>Vasculitis<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhinitis, cough, dyspnoea<sup>1</sup></p></td><td style="vertical-align:top"><p>Bronchospasm<sup>4</sup></p></td><td style="vertical-align:top"><p>Pneumonitis<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nausea<sup>4</sup>, abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting<sup>1</sup>, dysphagia<sup>1</sup></p></td><td style="vertical-align:top"><p>Constipation, gastritis, stomatitis, gastrointestinal inflammation (including aggravation of gastrointestinal inflammation), eructation</p></td><td style="vertical-align:top"><p>Gastro-intestinal haemorrhage<sup>4</sup>, duodenal ulcer, gastric ulcer, oesophageal ulcer, intestinal ulcer, and large intestinal ulcer, intestinal perforation; oesophagitis, melaena; pancreatitis, colitis<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic function abnormal, hepatic enzyme increased (including increased SGOT and SGPT)</p></td><td style="vertical-align:top"><p>Hepatitis<sup>4</sup></p></td><td style="vertical-align:top"><p>Hepatic failure<sup>4</sup>(sometimes fatal or requiring liver transplant), hepatitis fulminant<sup>4</sup>(some with fatal outcome), hepatic necrosis<sup>4</sup>, cholestasis<sup>4</sup>, hepatitis cholestatic<sup>4</sup>, jaundice<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash, pruritus (includes pruritus generalised)</p></td><td style="vertical-align:top"><p>Urticaria, ecchymosis<sup>4</sup></p></td><td style="vertical-align:top"><p>Angioedema<sup>4</sup>, alopecia, photo-sensitivity</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative<sup>4</sup>, erythema multiforme<sup>4</sup>, Stevens-Johnson syndrome<sup>4</sup>, toxic epidermal necrolysis<sup>4</sup>, drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>&nbsp;4</sup>, acute generalised exanthematous pustulosis (AGEP)<sup>4</sup>, dermatitis bullous<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia<sup>4</sup></p></td><td style="vertical-align:top"><p>Muscle spasms (leg cramps)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myositis<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased, blood urea increased</p></td><td style="vertical-align:top"><p>Renal failure acute<sup>4</sup>, hypo-natraemia<sup>4</sup></p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis<sup>4</sup>, nephrotic syndrome<sup>4</sup>, glomerulonephritis minimal lesion<sup>4</sup></p></td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Menstrual disorder<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px"><p>Infertility female (female fertility decreased)<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Influenza-like illness, Oedema peripheral/ fluid retention</p></td><td style="vertical-align:top"><p>Face oedema, chest pain<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Injury (accidental injury)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:66px">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="6" style="vertical-align:top; width:662px"><p><sup>1&nbsp;</sup>Adverse drug reactions that occurred in polyp prevention trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials). The adverse drug reactions listed above for the polyp prevention trials are only those that have been previously recognized in the post-marketing surveillance experience, or have occurred more frequently than in the arthritis trials.</p><p><sup>2&nbsp;</sup>Furthermore, the following&nbsp;<em>previously unknown</em>&nbsp;adverse reactions occurred in polyp prevention trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials):</p><p><strong>Common:</strong>&nbsp;angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased, benign prostatic hyperplasia, weight increased.&nbsp;<strong>Uncommon:&nbsp;</strong>helicobacter infection, herpes zoster, erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters, conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage, breast tenderness, lower limb fracture, blood sodium increased.</p><p><sup>3&nbsp;</sup>Women intending to become pregnant are excluded from all trials, thus consultation of the trial database for the frequency of this event was not reasonable.</p><p><sup>4&nbsp;</sup>Frequencies are based on cumulative meta-analysis with pooling of trials representing exposure in 38102 patients.</p><p>In final data (adjudicated) from the APC and PreSAP trials in patients treated with celecoxib 400 mg daily for up to 3 years (pooled data from both trials; see section 5.1 for results from individual trials), the excess rate over placebo for myocardial infarction was 7.6 events per 1000 patients (uncommon) and there was no excess rate for stroke (types not differentiated) over placebo.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>To report any side effects: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia: &nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp; Fax: + 966-11-205-7662</p><p>o&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; Email: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience of overdose. Single doses up to 1200 mg and multiple doses up to 1200 mg twice daily have been administered to healthy subjects for nine days without clinically<br />significant adverse effects. In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. Dialysis is unlikely to be an efficient method of drug removal due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Non-steroidal anti-inflammatory and antirheumatic drugs, NSAIDs, Coxibs, ATC code: M01AH01.<br />Mechanism of action<br />Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.<br />Pharmacodynamic effects<br />Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in human but its relevance to ulcer healing has not been established.<br />The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.<br />Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).<br />A dose dependent effect on TxB2 formation has been observed after high doses of celecoxib. However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.<br />Clinical efficacy and safety<br />Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of osteoarthritis of the knee and hip in approximately 4200 patients in placebo and active controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the inflammation and pain of rheumatoid arthritis in approximately 2100 patients in placebo and active controlled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg &ndash; 400 mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active controlled trials of up to 12 weeks duration. Celecoxib at doses of 100 mg BID, 200 mg QD, 200 mg BID and 400 mg QD in these studies demonstrated significant improvement in pain, global disease activity and function in ankylosing spondylitis.<br />Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (celecoxib doses from 50 mg &ndash; 400 mg BID). In twelve week endoscopy studies celecoxib (100 &ndash; 800 mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1000 mg per day) and ibuprofen (2400 mg per day). The data were inconsistent in comparison with diclofenac (150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration was not significantly different between placebo and celecoxib 200 mg BID and 400 mg BID.<br />In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study), 5,800 osteoarthritis and 2,200 rheumatoid arthritis patients received celecoxib 400 mg BID (4-fold and 2-fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800 mg TID or diclofenac 75 mg BID (both at therapeutic doses). Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&le;325 mg/day), primarily for cardiovascular prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statistically significant difference for complicated ulcers (relative risk 0.77, 95 % CI 0.41-1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk 0.66, 95% CI 0.45-0.97 but not between celecoxib and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid experienced 4 fold higher rates of complicated ulcers as compared to those on celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.<br />In a prospective randomised 24 week safety study in patients who were aged &ge;60 years or had a history of gastroduodenal ulcers (users of ASA excluded), the percentages of patients with decreases in haemoglobin (&ge;2 g/dL) and/or haematocrit (&ge;10%) of defined or presumed GI origin were lower in patients treated with celecoxib 200 mg twice daily (N=2238) compared to patients treated with diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily (N=2246) (0.2% vs. 1.1% for defined GI origin, p = 0.004; 0.4% vs. 2.4% for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).<br />Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps<br />Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.<br />In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects) respectively, compared to 0.9% (6/679 subjects) for placebo. The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.<br />In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was 1.0% (9/933 subjects) with celecoxib 400 mg once daily and 0.6% (4/628 subjects) with placebo.<br />Data from a third long-term study, ADAPT (The Alzheimer&#39;s Disease Anti-inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200 mg BID compared to placebo. The relative risk compared to placebo for a similar composite endpoint (cardiovascular death, myocardial infarction, stroke) was 1.14 (95% CI 0.61 - 2.12) with celecoxib 200 mg twice daily. The incidence of myocardial infarction was 1.1% (8/717 patients) with celecoxib 200 mg twice daily and 1.2% (13/1070 patients) with placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours. Dosing with food (high fat meal) delays absorption of celecoxib by about 1 hour resulting in a Tmax of about 4 hours and increases bioavailability by about 20%.<br />In healthy adult volunteers, the overall systemic exposure (AUC) of celecoxib was equivalent when celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant alterations in Cmax, Tmax or T1/2 after administration of capsule contents on applesauce.<br />Distribution<br />Plasma protein binding is about 97 % at therapeutic plasma concentrations and the drug is not preferentially bound to erythrocytes.<br />Biotransformation<br />Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate.<br />Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.<br />In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median Cmax and AUC0-24 of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC0-24 increased by approximately 3-fold compared to normal metabolisers. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3-1.0% among different ethnic groups.<br />Patients who are known, or suspected to be CYP2C9 poor metabolisers based on previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution (see section 4.2).<br />No clinically significant differences were found in PK parameters of celecoxib between elderly African-Americans and Caucasians.<br />The plasma concentration of celecoxib is approximately 100% increased in elderly women (&gt;65 years).<br />Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in Cmax of 53% and in AUC of 26% of celecoxib. The corresponding values in patients with moderate hepatic impairment were 41% and 146% respectively. The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values. Treatment should be initiated at half the recommended dose in patients with moderate liver impairment (with serum albumin 25-35<br />g/l). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been studied and celecoxib is contraindicated in this patient group.<br />There is little experience of celecoxib in renal impairment. The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients. Thus, caution is advised when treating patients with renal impairment. Severe renal impairment is contraindicated.<br />Elimination<br />Celecoxib is mainly eliminated by metabolism. Less than 1 % of the dose is excreted unchanged in urine. The inter-subject variability in the exposure of celecoxib is about 10-fold. Celecoxib exhibits dose- and time-independent pharmacokinetics in the therapeutic dose range. Elimination half-life is 8-12 hours. Steady state plasma concentrations are reached within 5 days of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of repeated dose toxicity, mutagenicity or carcinogenicity beyond those addressed in section 4.4, 4.6, and 5.1 of the SmPC.<br />Celecoxib at oral doses &ge;150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily as measured by AUC0-24), caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed when rats were given celecoxib at oral doses &ge;30 mg/kg/day (approximately 6-fold human exposure based on the AUC0-24 at 200 mg twice daily) throughout organogenesis. These effects are expected following inhibition of prostaglandin synthesis. In rats, exposure to celecoxib during early embryonic development resulted in pre-implantation and post-implantation losses, and reduced embryo/fetal survival.<br />Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.<br />In a 2 year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, croscarmellose sodium, sodium lauryl sulfate, povidone, magnesium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Immediate packaging</p></td><td style="vertical-align:top"><p>Outer packaging</p></td></tr><tr><td style="vertical-align:top"><p>Aluminum foil/ PVC Blister</p></td><td style="vertical-align:top"><p>Carton</p><p>Leaflet</p></td></tr></tbody></table><p>&nbsp;</p><p>Pedexa<sup>&Ograve;</sup> 100 mg capsules are available in packs of 20 capsules (2 blisters of 10).</p><p>Pedexa<sup>&Ograve;</sup> 200 mg capsules are available in packs of 10 capsules (one blister) and 30 capsules (3 blisters of 10).</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O. Box 9364
Na'ur – Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/05/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>